

Nuplazid (pimavanserin)

- FDA-approved for treatment of psychosis in Parkinson's disease
- Pharmacology
 - Serotonin inverse agonist/antagonist
 - 34 mg/day
 - 17 mg tabs
 - No appreciable binding to
 - Dopamine receptors
 - Histamine receptors
 - Muscarinic receptors
 - Adrenergic receptors
 - 3A4 metabolism
- Side effects
 - Peripheral edema: 7% vs. 2% with placebo
 - Nausea: 7% vs. 4% with placebo
 - Confusional state: 6% vs. 3% with placebo
 - Hallucination: 5% vs. 3% with placebo
 - Constipation: 4% vs. 3% with placebo
 - Gait disturbance: 2% vs. <1% with placebo
 - Prolongs QTc